National Institutes of Health (NIH)
NEWS
There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
The $3.1 million NCATS grant will help the company test SPI-1005 in two trials, both OK’d by the U.S. Food and Drug Administration (FDA) last August.
What has been learned about SARS-CoV-2, the virus that causes COVID-19, in only about 15 months, is truly a historical scientific achievement. And new information continues to come in.
The announcement by the NIAID, a part of the National Institutes of Health (NIH), is very unusual.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.
The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the COVID-19 pandemic.
JOBS
IN THE PRESS